Kesmalea Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $12.9M

  • Investors
  • 3

Kesmalea Therapeutics General Information

Description

Developer of a pipeline of therapeutics designed to transform large protein degraders into small molecules for targeted protein degradation. The company's platform enables the creation of oral, CNS-penetrant degraders by inserting reversible linkers, allowing patients with chronic diseases such as oncology and CNS disorders to access innovative treatments.

Contact Information

Website
www.kesmalea.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2nd Floor, 8 Bloomsbury Street
  • London WC1B 3SR
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 2nd Floor, 8 Bloomsbury Street
  • London WC1B 3SR
  • England, United Kingdom

Kesmalea Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kesmalea Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 29-Aug-2024 $12.9M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 22-Dec-2022 Completed Pre-Clinical Trials
1. Angel (individual) 02-Dec-2020 $557K $557K Completed Pre-Clinical Trials
To view Kesmalea Therapeutics’s complete valuation and funding history, request access »

Kesmalea Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A Preferred
To view Kesmalea Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Kesmalea Therapeutics Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Kesmalea Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202302402-D0 Composition Inactive 20-Feb-2023

Kesmalea Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kesmalea Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioInnovation Institute Accelerator/Incubator Minority
Oxford Science Enterprises Venture Capital Minority
Syncona Venture Capital Minority
To view Kesmalea Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Kesmalea Therapeutics FAQs

  • When was Kesmalea Therapeutics founded?

    Kesmalea Therapeutics was founded in 2020.

  • Where is Kesmalea Therapeutics headquartered?

    Kesmalea Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Kesmalea Therapeutics?

    Kesmalea Therapeutics has 24 total employees.

  • What industry is Kesmalea Therapeutics in?

    Kesmalea Therapeutics’s primary industry is Drug Discovery.

  • Is Kesmalea Therapeutics a private or public company?

    Kesmalea Therapeutics is a Private company.

  • What is the current valuation of Kesmalea Therapeutics?

    The current valuation of Kesmalea Therapeutics is .

  • What is Kesmalea Therapeutics’s current revenue?

    The current revenue for Kesmalea Therapeutics is .

  • How much funding has Kesmalea Therapeutics raised over time?

    Kesmalea Therapeutics has raised $37.8M.

  • Who are Kesmalea Therapeutics’s investors?

    BioInnovation Institute, Oxford Science Enterprises, and Syncona have invested in Kesmalea Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »